Publication | Open Access

Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine

Medicinal ChemistryTumor-activated ProdrugMedicineCombination TherapyPharmacotherapyAnti-cancer AgentDrug DevelopmentPharmacologyRadiation OncologyDihydropyrimidine DehydrogenaseDrug Discovery